Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling

1 Jan 2007

Abstract excerpt

Pertuzumab (Omnitarg, rhuMab 2C4) is a humanized monoclonal antibody, which inhibits HER2 dimerization. Because it has shown some clinical activity in ovarian cancer, this study sought to identify predictors of response to this agent in a model of ovarian cancer. A panel of 13 ovarian cancer cell lines was treated with heregulin beta1 (HRGbeta1) or transforming growth factor-alpha, and cell proliferation was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Adhesion Molecules Research
Share to HER2/EGFR in Cancer Research
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 17237269
DOI: 10.1158/1535-7163.mct-06-0401

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signalingPMID 17237269Read ↗

Modulation of HER3 Is a Marker of Dynamic Cell Signaling in Ovarian Cancer: Implications for Pertuzumab SensitivitySemantic proximity Read ↗

Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancerSemantic proximity Read ↗

Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancerSemantic proximity Read ↗

HER4 Mediates Ligand-Dependent Antiproliferative and Differentiation Responses in Human Breast Cancer CellsSemantic proximity Read ↗

Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies.Semantic proximity Read ↗

Engineered bivalent ligands to bias ErbB receptor-mediated signaling and phenotypes.Semantic proximity Read ↗

Implications of EGFR inhibition in ovarian cancer cell proliferation.Semantic proximity Read ↗

Characteristics of EGFR family-mediated HRG signals in human ovarian cancerSemantic proximity Read ↗

A Central Role for HER3 in <i>HER2</i> -Amplified Breast Cancer: Implications for Targeted TherapySemantic proximity Read ↗

Heregulin regulates the actin cytoskeleton and promotes invasive properties in breast cancer cell lines.Semantic proximity Read ↗

Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell linesSemantic proximity Read ↗

HER2 Oncogenic Function Escapes EGFR Tyrosine Kinase Inhibitors via Activation of Alternative HER Receptors in Breast Cancer CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.